PRICE T ROWE ASSOCIATES INC /MD/
Position in LYEL — Lyell Immunopharma, Inc.
CIK 80255
BALTIMORE, MD
Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$263,347
-$140,732 QoQ
Shares Held
13,128
0.0% QoQ
Ownership
0.056%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PRICE T ROWE ASSOCIATES INC /MD/ holds $14,300,473,279 across 256 Biotechnology names. LYEL ranks #209 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
3,374,955 | $2,464,560,888 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,177,527 | $1,682,444,460 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,760,122 | $785,964,877 | |
| 4 | INSM |
INSMED Inc
|
3,092,807 | $505,735,799 | |
| 5 | KYMR |
Kymera Therapeutics, Inc.
|
6,060,847 | $504,807,946 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,432,748 | $474,053,330 | |
| 7 | ASND |
Ascendis Pharma A/S
|
1,530,345 | $350,035,811 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
3,232,213 | $314,332,713 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $263,347 | 13,128 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $404,079 | 13,128 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $213,198 | 13,128 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $2,705,561 | 306,059 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||